fregime
TODAYSTOCKSARCHIVEABOUTGUIDE
Sign inFollow your stocks

Write what you believe about your stocks; every morning the cited record grades it: supported, challenged, or untouched. Never opinions.

Development · 12 Sep 2026

GLENMARK, full dossier

Glenmark Specialty S.A. announced the launch of RYALTRIS® Nasal Spray in Brazil for the treatment of moderate to severe symptoms associated with allergic rhinitis.

2 publishers have reported this development. Each act of reporting is below, cited.

The record

Glenmark Specialty S.A. announced the launch of RYALTRIS® Nasal Spray in Brazil for the treatment of moderate to severe symptoms associated with allergic rhinitis.

capitalmarket.com11 Sep 2026

Glenmark Pharmaceuticals announced the launch of RYALTRIS® Nasal Spray in Brazil for the treatment of moderate to severe symptoms associated with allergic rhinitis in adults and adolescents of 12 years of age and older.

capitalmarket.comexpresspharma.in11 Sep 2026

Glenmark Pharmaceuticals

₹2,331.00

▼ -0.16%

Close (EOD), as of 1 Oct 2026 · source

Glenmark Pharmaceuticals: results, dividends, orders, the full cited record →

More on Glenmark Pharmaceuticals

Symbiotec Pharmalab announced the receipt of an establishment inspection report (EIR) from the U.S. Food and Drug Administration (US FDA) for its manufacturing facility in Pithampur (SEZ), Madhya Pradesh, with a voluntary action indicated (VAI) status.

30 Sep 2026 · 7 publishers

Two more persons were arrested in Uttarakhand in connection with the spurious Telma-AM tablets investigation.

28 Sep 2026 · 1 publisher

Dr Reddys Laboratories Ltd is quoting at Rs 1213, up 0.17% on the day as on 12:44 IST on the NSE.

24 Sep 2026 · 2 publishers

India's 10 largest pharmaceutical companies have maintained positive average volume growth through every month of 2026 so far, while smaller rivals have seen a more uneven performance.

20 Sep 2026 · 1 publisher

Zydus Lifesciences and Glenmark Pharma recorded the highest growth among Nomura's coverage universe in August 2026, while semaglutide generics sales rose 2% month-on-month.

10 Sep 2026 · 1 publisher

Every claim carries its citation

This page is the corroborated record of one development: what each credible source reported, linked and dated. We compile and cite; we do not opine.

New here? The reader's guide explains every page, plate by plate.

fregime is informational research software. Content on this page is factual reporting compiled from cited public sources; nothing here is advice, and nothing here expresses an opinion on any security. fregime is not registered with SEBI as an investment adviser or research analyst. Before making investment decisions, consult a SEBI-registered adviser. Price figures are delayed end-of-day values cited to the exchange's published file, never live quotes.